ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

ClinicalTrials.gov ID: NCT04935879

Public ClinicalTrials.gov record NCT04935879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Study identification

NCT ID
NCT04935879
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
241 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 3, 2021
Primary completion
Jun 5, 2024
Completion
Jun 5, 2024
Last update posted
Dec 1, 2025

2021 – 2024

United States locations

U.S. sites
22
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
University of South Alabama Children's and Women's Hospital Mobile Alabama 36604
University of South Alabama Mitchell Cancer Institute Mobile Alabama 36604
University of South Alabama Strada Patient Care Center Mobile Alabama 36604
Arkansas Children's Hospital Little Rock Arkansas 72202
UC Irvine Health Orange California 92868
UCI Center for clinical research Orange California 92868
Uconn Health/Uconn John Dempsey Hospital/Neag Comprehensive Cancer Center/New England Sickle Cell Farmington Connecticut 06030
Hospital Pharmacy Services- Investigational Drug Services Chicago Illinois 60612
Rush University Medical Center Investigator Pharmacy Chicago Illinois 60612
Rush University Medical Center Chicago Illinois 60612
University of Illinois Clinical Research Center (CRC) Chicago Illinois 60612
University of Illinois Hospital and Health Sciences System(UI Health) Chicago Illinois 60612
Dana-Farber Cancer Institute IDS Pharmacy Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Hospitals - Michigan Medicine Ann Arbor Michigan 48109
Jacobi Medical Center The Bronx New York 10461
Duke University Medical Center Durham North Carolina 27705
DUMC Investigational Drug Services Pharmacy Durham North Carolina 27710
McGovern Medical School/Health Science Center Houston Houston Texas 77030
Memorial Hermann - TMC Investigational Drugs, IDS Pharmacy Houston Texas 77030
Memorial Hermann Hospital, Texas Medical Center - Clinical Research Unit (CRU) Houston Texas 77030
UT Physicians Comprehensive Sickle Cell Clinic Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04935879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04935879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →